scorecardresearch
Monday, September 22, 2025
TopicCovishield

Topic: Covishield

Akhilesh’s claims about Covishield vaccine are baseless, says Union MoS for health SP Singh Baghel

SP chief has been raising alarm about Oxford-AstraZeneca vaccine, but Baghel points to WHO approval. Minister also confident of retaining his Agra seat, which is voting Tuesday.

How safe is AstraZeneca Covid vaccine & why there is no need to panic — some key questions answered

51 cases have been lodged in a UK court against biopharma company over claims that its Covid vaccine caused death and injury in several cases.

Don’t let anti-vaxxers weaponise AstraZeneca furore. Vaccines are safe—and we are the proof

Vaccines have eliminated two diseases—smallpox in humans and rinderpest in cattle. If they were killing one in 50,000 people, we wouldn’t be rolling them out across the globe for decades.

AstraZeneca reaffirms Covid vaccine’s safety amid rare side effect concerns

AstraZeneca recently acknowledged that its Covid vaccine Covishield & Vaxzevria 'can, in very rare cases, cause Thrombosis Thrombocytopenia Syndrome'.

AstraZeneca vaccine safe, effective in kids, finds Lancet study. WHO still says for adults only

The vaccine, marketed as Covishield in India, induced antibody concentrations in children similar to those associated with high efficacy in adults, says study by UK researchers.

Didn’t suit global narrative that Indian firm could deliver quality, says SII’s Poonawalla

CEO of world’s largest vaccine maker says India is better equipped to deal with pandemics now, adds a global treaty is important to allow resource-sharing across borders.

‘No demand’: In Covishield’s home Pune, 1.41 lakh doses at private centres about to expire

Private hospitals in Pune municipal limits are staring at major vaccine wastage, blame free government drives and strict rules for booster eligibility and second dose gap.

Why you won’t get Covishield, Covaxin at a chemist yet, despite full market approval

Covishield and Covaxin have been fully authorised only for use in adults, and can only be used in a ‘programmatic setting’, which means you’ll still have to register on CoWin.

DCGI grants regular market approval to Covishield, Covaxin for use in adult population

Approval was granted under New Drugs & Clinical Trials Rules, 2019 citing conditions that Bharat Biotech & SII will submit clinical trials' data & vaccines will be supplied for programmatic setting.

Covishield, Covaxin prices may drop to Rs 275/dose after getting regular market approval

Bharat Biotech's Covaxin is currently priced at Rs 1,200 per dose while SII's Covishield costs Rs 780 at private facilities. Both the vaccines are only authorised for emergency use.

On Camera

India’s IT firms must reduce dependence on North America, think long term

India’s IT services companies are not holding firms. They should focus on creating long-term value for shareholders instead of returning cash to keep share values up.

Market regulator SEBI clears Adani Group of impropriety alleged by Hindenburg Research

SEBI probe concluded that purported loans and fund transfers were paid back in full and did not amount to deceptive market practices or unreported related party transactions.

60 yrs on, veterans recall lessons from 1965 India-Pakistan war. ‘Equipment alone doesn’t win battles’

A common thread runs through the memories of soldiers of the 1965 war—ingenuity, courage and camaraderie that withstood an apparently technologically superior foe.

India doesn’t give walkovers to Pakistan in war. Here’s why it shouldn’t do it in cricket either

Many really smart people now share the position that playing cricket with Pakistan is politically, strategically and morally wrong. It is just a poor appreciation of competitive sport.